Dr. Khaled Assi,

Associate Professor

Biography

Dr Khaled H Assi was awarded the PhD in pharmaceuticalanalysis by the University of Bradford, in 1999. He then took up a postdoctoralpost at university of Bradford between 1999-2001 working on the inhaledtherapies. His postdoctoral program was extended for one more year through anawarded grant from Glaxo SmithKline. In 2002, he was accepted a researchfellowship at Bradford School of Pharmacy. Dr Assi was appointed as a Lecturerat the Bradford School of Pharmacy and then promoted to senior lecturer , in March2016 and has continued developing his research in the inhaled therapies area.In this position he is teaching the MPharm students at different levels and heis also leading the MSc Pharmaceutical Technology and Medicines Controlprogramme. The modules he delivers cover the area of respiratory drug delivery,pharmaceutical analysis, Quality assurance and quality control ofpharmaceuticals. He is also active in the research. His principal research interests lie in the fieldof drug delivery to the lung, this encompass formulation development forinhalation products. The work involves the development of new formulations forinhaled products including dry powder, nanosuspension and nanoemaulsion for both dry powderinhalers and nebulisers. It also involves selecting a suitable inhalationdevice for doses of dry powder inhalers and nebulised solutions based on thetargeted peripheral lung areas for both locally and systemically actingpharmaceuticals. He also has researchinterest in the following: o Determination of the in-vitro characteristics ofinhaled products and assessing the in-vitro quality of the dose emitted frominhalation systems (dry powder inhalers [DPIs], metered dose inhalers [MDIs]and nebulisers) and in the determination of the resistance characteristics andcomparative product features of various marketed DPIs to identify the optimuminhalation flow rate and appropriate DPI for different patients. In additionto the inhaled therapy I have research in the development of pharmaceutical andbioanalytical assay methods. This includes the optimisation and validation ofbioanalytical techniques for qualitative and quantitative determination ofinhaled drugs and its metabolites in aqueous and biological fluids forbioequivalence and pharmacokinetic studies.